TransMedics Group Inc (TMDX)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	35,780	32,654	1,480	-11,653	-26,671	-37,235	-17,713	-28,234	-36,165	-42,115	-47,661	-46,822	-44,179	-37,829	-29,958	-27,787	-28,716	-31,582	-34,770	-35,464
Revenue (ttm)	US$ in thousands	441,540	401,090	358,759	296,919	241,623	191,824	151,077	119,133	93,459	71,752	51,439	39,089	30,262	28,221	29,942	25,162	25,639	24,069	24,183	26,458
Pretax margin		8.10%	8.14%	0.41%	-3.92%	-11.04%	-19.41%	-11.72%	-23.70%	-38.70%	-58.70%	-92.66%	-119.78%	-145.99%	-134.05%	-100.05%	-110.43%	-112.00%	-131.21%	-143.78%	-134.04%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $35,780K ÷ $441,540K
= 8.10%

TransMedics Group Inc's pretax margin experienced a significant improvement over the historical period analyzed. The margin was consistently negative from March 31, 2020, to June 30, 2022, indicating that the company's expenses exceeded its earnings before taxes during this period. However, starting from September 30, 2022, the pretax margin showed a positive trend, indicating that the company's profitability before taxes improved steadily. By December 31, 2024, the pretax margin reached 8.10%, reflecting a turnaround in the company's operational efficiency and financial performance. This positive pretax margin trend suggests that TransMedics Group Inc's cost management and revenue generation strategies have been successful in driving profitability and creating value for its stakeholders.